and are pharmaceutically equivalent and bioequivalent, whereas authorized generic drugs (AGs) contain both identical active and inactive ingredients as their corresponding brand drugs but are marketed as generics. This study compares generic-to-brand switchback rates between generic and AGs. DESIGN Retrospective cohort study. DATA SOURCE Claims and electronic health record data from a regional U.S. health care system. PATIENTS The full cohort consisted of 5542 unique patients who received select branded drugs during the 6 months prior to their generic drug market availability (between 1999 and 2014) and then were switched to an AG or generic drug within 30 months of generic drug entry. For these patients, 5929 unique patient-drug combinations (867 with AGs and 5062 with generic drugs) were evaluated. MEASUREMENTS AND MAIN RESULTS Ten drugs with AGs and generics marketed between 1999 and 2014 were evaluated. The date of the first generic prescription was considered the index date for each drug, and it marked the beginning of follow-up to evaluate the occurrence of generic-to-brand switchback patterns over the subsequent 30 months. Switchback rates were compared between patients receiving AGs versus those receiving generics using multivariable Cox proportional hazards models, controlling for individual drug effects, age, sex, Charlson Comorbidity Score, pre-index drug use characteristics, and pre-index health care utilization. Among the 5542 unique patients who switched from brand to generic or brand to AG, 264 (4.8%) switched back to the brand drug. Overall switchback rates were similar for AGs compared with generics (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.65-1.15). The likelihood of switchback was higher for alendronate (HR 1.64, 95% CI 1.20-2.23) and simvastatin (HR 1.81, 95% CI 1.30-2.54) and lower for amlodipine (HR 0.27, 95% CI 0.17-0.42) compared with the other drugs evaluated. CONCLUSION Overall switchback rates were similar between AG and generic drug users, indirectly supporting similar efficacy and tolerability profiles for brand and generic drugs. Reasons for differences in switchback rates among specific products need to be explored further.
Generic drugs play an important cost-saving role in the U.S. health care system. In 2012 alone, a health care savings of $217 billion was attributed to generic drug use. 1 Not all patients and providers, however, are willing to use generic drugs. This is due partially to previous studies suggesting that generic and brand drugs are not perfectly interchangeable. 2, 3 Patients' or physicians' personal opinions about generic drugs also may affect their acceptance, which can indirectly affect the perceived safety and efficacy of generic drugs. [4] [5] [6] [7] [8] [9] For example, a 2016 national survey found that 13% of respondents believed branded drugs are more effective than generics, and 20% of respondents believed generic drugs have different adverse effects than branded drugs. 10 In a parallel survey of physicians, 11% of physicians expressed negative perceptions about the efficacy of generic drugs, and 27% believed they caused more adverse effects. 11 So although generic drugs can clearly save health care dollars, some doubt remains among the patient and provider communities about whether generic and brand drugs yield the same outcomes.
In lieu of the randomized controlled trials required for a branded drug approval via a New Drug Application (NDA), generic drugs are approved via an Abbreviated New Drug Application (ANDA) because safety and efficacy of the active pharmaceutical ingredient was established during the approval process for the branded drug. Generic drug applications are termed "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. The ANDA requires generic drugs to demonstrate pharmaceutical equivalence and bioequivalence by showing that the same amount of active drug ingredient reaches the bloodstream of healthy patients in the same amount of time (i.e., bioavailability). 12 Therefore, although pharmaceutical equivalence and bioequivalence are established for generic drugs, therapeutic equivalence is assumed and not tested directly.
Instead of direct testing of therapeutic equivalence, postmarketing evaluation of brand versus generic utilization behavior and outcomes can help provide indirect evidence to support or refute their comparability. Several studies have taken such an approach. [13] [14] [15] [16] One study 13 followed a prospective cohort of 58 patients with epilepsy to assess the brand-generic interchange of levetiracetam, as well as the incidence of selfreported adverse events and loss of seizure control. No statistically significant differences were found in the number of adverse events or seizures in patients before the generic switch versus 6 months after the switch, with an overall 3.4% switchback to brand-name medication. Similarly, using Medicaid claims data in a retrospective crossover cohort study of 616 patients, another study 14 found no statistically significant increase in hospitalizations or emergency department visits after brand-generic switch for lamotrigine. This is consistent with earlier findings, 15 in which a retrospective cohort of patients who switched from brand-name to generic lamotrigine, divalproex, or phenytoin were compared with a cohort of brand-name medication users of these drugs. A recent prospective cohort study 16 found no statistically significant differences in intraocular pressure for patients with glaucoma after switching from brand to generic dorzolamide-timolol ophthalmic drops.
Although previous studies provide a foundation for postmarketing surveillance of brand versus generic switching and clinical outcomes, the methods seen thus far do not adequately address selection bias (e.g., price and access may differentially affect who gets brand vs who gets generic); nor do they account for patient and provider perceptions of generic drugs that can impact prescribing and health care utilization patterns. Authorized generic drugs (AGs) provide an interesting research opportunity for overcoming these biases. AGs contain the same active and inactive ingredients as the branded product, authorized under the same NDA. The only difference is that they are labeled and marketed as generic drugs. 17 This is in contrast to ANDA-approved generics (henceforth referred to as simply "generics"). Clinical outcomes of these generics are not directly compared with the reference-listed product. Because AGs and generics are not differentiated in their prescribing, payment, or distribution to patients (i.e., they are both treated and perceived to be "generics"), any biases should be equally applied to both products. Therefore, we compared AG and generic utilization patterns as a proxy for a brand versus generic comparison. We considered the act of switching back to a brand product after trying a generic product to be a broad marker for lack of generic efficacy or tolerability. Under this assumption, we compared AG-to-brand and generic-to-brand switchback rates. Results of our analyses can help determine if postmarketing evidence supports potential differences between brand-name and generic drugs, even after minimizing potential selection and perception biases.
Methods

Study Design
In this retrospective cohort study, patients received select branded drugs prior to generic drug market entry and then were switched to an AG or generic within 30 months of generic entry ( Figure 1 ). The drugs included in this study (Table 1) were selected based on evidence that both an AG and generic were marketed at some point between 1999 and 2014, with a sufficient sample of users (30 or more) in our study data. These drugs included alendronate (Fosamax), amlodipine (Norvasc), citalopram (Celexa), gabapentin (Neurontin), glimepiride (Amaryl), losartan (Cozaar), metformin extended release (ER) (Glucophage XR), paroxetine (Paxil), sertraline (Zoloft), and simvastatin (Zocor). The sample of drugs was not designed to reflect a homogeneous class of agents, but rather this diverse group of agents allowed examination across a broad market of agents. The date of the first generic prescription in our data was considered the index date for each drug, and it marked the beginning of follow-up to evaluate genericto-brand switchback patterns over the subsequent 30 months. The National Drug Code was used to differentiate brand, AG, and generic drugs. The drugs were first considered as individual cohorts and then combined as an aggregated cohort with time anchored to the index date for each patient-drug combination. Combined analyses controlled for individual drug effects. Unless otherwise specified, results are shown for the combined population.
The study was approved by the institutional review boards of the Marshfield Clinic Research Foundation and Auburn University, and by the U.S. Food and Drug Administration Research Involving Human Subjects Committee.
Data
Administrative claims data from a regional insurance provider (Security Health Plan [SHP]) were combined with electronic health record data from the Marshfield Clinic, an integrated health care delivery system that provides most of the health care services to 1.5 million patients residing in more than 50 locations in northern, central, and western Wisconsin. On average, 102,700 SHP-insured beneficiaries have full-year insurance coverage, and~65% of the SHP population with full-year insurance coverage have evidence of use of Marshfield Clinic clinics and providers. The research data warehouse used for this study did not contain charge or reimbursement-related fields for the SHP claims.
Study Sample
Data from 1999 through 2014 were used to apply the following inclusion criteria for the study sample: patients had to have received at least one brand prescription drug of interest during the 6 months of pre-generic availability and at least one AG or generic prescription drug of interest within 30 months of generic drug entry. Patients also had to have had continuous enrollment in the 6 months prior to generic introduction and through at least the first generic prescription fill, with continuous enrollment defined as no gaps in enrollment greater than 31 days.
Main Outcome Measures
Generic-to-brand switchback was defined as a patient switching from the AG or generic product back to the branded drug. We assumed that the first dispensing date of the brand drug following AG or generic dispensing reflected the date of the patient's switchback. Patients who continued to receive the generic drug throughout the 30-month observation period or who discontinued treatment were defined as no switchback. Treatment discontinuation was defined as a gap in medication supply exceeding 90 days, and follow-up time for these individuals was censored at the time of discontinuation (i.e., date of last available medication supply).
Covariates
Covariates were measured during the 6-month pre-index period and included demographics (age and sex), type of insurance, proportion of a patient's prescriptions for other medications that were filled with a brand drug, defined daily dosage of the last prescription prior to generic switch, 18 Charlson Comorbidity Index, 19 any preindex all-cause hospitalizations, any pre-index all-cause emergency department visits, number of pre-index outpatient visits, and monotherapy or polytherapy status for the condition being treated (polytherapy defined as two or more different medications used in the same therapeutic class of interest).
Statistical Analysis
Descriptive statistics were used to summarize the characteristics of patients who did and did not switch back to brand drugs, with the switchbacks stratified by whether they were using an AG or generic drug. Independent sample t tests and v 2 tests were used to compare continuous and categorical characteristics, respectively, between the switchback and non-switchback group as well as between the AG and generic switchback groups. Time to the "next change" after the initial generic switch from brand to generic was illustrated separately for the AG versus generic switch groups, following patients for up to 12 months after the initial generic switch. The "next change" was based on the first appearance of brand or the alternative type of generic. Multivariable Cox proportional hazards models were used to evaluate factors associated with the time to switchback, reporting the median estimated hazard ratio (HR) and 95% confidence interval (CI) across 1000 bootstrapped samples. In this analysis, patients were assigned to the last generic product they used before a brand switchback (i.e., we allowed movement among generics). We used the COVSANDWICH option in the SAS statement PROC PHREG, adjusting the standard errors with robust covariance estimates to control for within-individual correlation. The covariates for insurance type and polypharmacy were excluded from this analysis because almost all of the sample had commercial insurance, and polypharmacy was similar across the sample. Because of market fluctuations in AG and generic availability, follow-up time was censored at the earliest time when we stopped observing claims for either the AG or all existing generics. This prevented detection of brand switchbacks that may have been driven by lack of product availability. All analyses were performed with SAS v.9.3 (SAS Institute, Inc., Cary, NC), and the statistical significance was set at p<0.05.
Results
The final sample included 5929 unique patient-drug combinations, representing 5542 unique patients who received at least one included brand drug and then switched to a generic. Table 2) . Compared with patients who did not switch back to brand, the patients who switched back to brand tended to be older (mean 64.4 vs 60.3 yrs) and more commonly female (79.2% vs 68.6%), and they used a greater proportion of brand medications during the pre-index period (mean proportion 62.0% vs 58.6%). Comparing characteristics of patients who switched back to brand from the AG group versus the generic group, patients switching to brand from the AG group were more commonly male (31.3% vs 17.3% male) and used a lower defined daily dose of the medication of interest during the pre-index period (mean 1.1 vs 1.2 defined daily doses). All other demographics were similar between the switchback and no switchback groups, as well as between the switchback from AG and switchback from generic groups (p>0.05 for all comparisons).
For the most part, the switchback rates for each included drug were similar between the AG and the generic groups, but some individual drugs had a relatively small sample size, and Figure 2 illustrates these data.
In the evaluation of unadjusted utilization patterns for each drug, a general trend toward a higher percentage of switchbacks was noted for the AG groups compared with the generic groups (e.g., amlodipine, paroxetine, glimepiride, citalopram, losartan, metformin XR, and simvastatin). Part of this trend might be explained by the more volatile usage patterns we observed for AGs (Figure 3 ). For example, panel A of Figure 3 illustrates the time to the next medication change after the initial switch from brand to generic drug. By 12 months,~50% of the AG users had switched to a different product, and most of these switchers were moving to a generic rather than back to the branded product. In contrast, panel B of Figure 3 illustrates that patients initially switching to the generic were more likely to remain on a generic after 12 months, with more than 85% of the generic users continuing to receive a generic. The greater overall product switching patterns for AG drugs could be involved in the AG-to-brand switchback trends we observed.
In the Cox proportional hazards models (Table 3) , the overall rate of AG-to-brand and generic-to-brand switchbacks were similar (HR 0.86, 95% CI 0.65-1.15). Significant covariates included age (HR 1.02, 95% CI 1.01-1.02), sex (reference = female; HR 0.59, 95% CI 0.44-0.80), and proportion of pre-index brand medication use (HR 2.43, 95% CI 1.45-4.07). The proportional hazards model also showed specific Figure 2 . Unadjusted brand switchback rates for patients who received authorized generic drugs and independent generic drugs for each drug included in the study, as well as the rate for all drugs combined. illustrates that by 12 months,~50% of the authorized generic drug users (dotted line) had switched to a different product, and most of these switchers were moving to a generic (dashed line) rather than back to the branded product (continuous line). In contrast, panel B illustrates that patients initially switching to the generic were more likely to remain on a generic after 12 months (dashed line), with more than 85% of the generic users continuing to receive a generic. A similar proportion of these switchers were moving to an authorized generic (dotted line) as those moving back to a branded product (continuous line).
drug type to have a conditional effect on generic-to-brand switchback, with simvastatin (HR 1.81, 95% CI 1.30-2.54) and alendronate (HR 1.64, 95% CI 1.20-2.23) showing a higher likelihood of switchback, and amlodipine (HR 0.27, 95% CI 0.17-0.42) showing a lower likelihood of switchback. Other covariates and individual drugs were not statistically significantly associated with switchback (p>0.05).
Discussion
Although generic drugs have high cost savings, debate in the literature is ongoing about whether brands and generics have clinically equivalent efficacy and tolerability. [1] [2] [3] This study identified a cohort of patients who switched from a brand to a generic drug and then quantified generic-to-brand switchback rates. We minimized study design bias that can be introduced by patient and provider perceptions of generic drugs by comparing these switchback patterns among patients using AGs (brand drug proxy) as opposed to generics. Overall, we found a similar likelihood of generic-to-brand switchbacks between AG and generic users (p>0.05). This finding suggests that after accounting methodologically for generic drug perception biases that may complicate interpretation of generic and brand utilization patterns, and controlling for other factors that could influence the likelihood of switching from a generic back to a brand drug, the evidence is not sufficient to indicate that differences between ANDA-approved products (our generic group) and the reference-listed drug (our AG group) are driving generic-tobrand switchbacks. Broadly speaking, the policy implication of this conclusion is that switchbacks from generic to brand are likely not related to specific differences between ANDAand NDA-approved products.
Overall, in our cohort we observed generic-tobrand switchbacks in 4.8% of the population taking one of the study drugs. These results are relatively consistent with those seen in previous studies including a 3.4% generic-to-brand switchback for levetiracetam 13 and a 7.1% generic-to-brand switchback for statin users. 20 The statin study 20 also found that the likelihood of generic-to-brand switchback increased with dose (16.1% for the highest simvastatin dose), patient age, and comorbidities, concluding that older and sicker patients may be more sensitive to adverse effects and efficacy considerations. Although we also found older age to be related to switchback, we did not find dose or comorbidities (measured by the Charlson score) to be statistically significantly related to switchback in our overall cohort or even in the cohort of just simvastatin users (data not shown). We did, however, find female sex and higher proportions of pre-index brand medication use to be predictive of a higher likelihood of generic-to-brand switchback. Our finding of female sex and preindex brand preferences provides a further indication that personal preferences and characteristics are important factors to consider in generic drug use. Although we were unable to measure factors such as income, education, race/ethnicity, or health education background, 21 these characteristics also could be important and should be considered in future studies.
Although we found overall that generic-tobrand switchback rates were similar for AGs and generics, our finding of differential switchback rates for specific drugs is important to consider. For example, compared with the overall cohort, we observed differential switchback rates for The drugs in which we observed a higher (or lower) than average generic-to-brand switchback rate are particularly interesting. Part of the explanation may be related to shorter periods of AG availability, although our analyses were censored at the last observed claim date for each drug. We believe some of the differences may be explained by other factors that we could not control. For instance, for simvastatin, the higher switchback rate may be an artifact of insurance and market-level dynamics during the time that generic simvastatin was introduced (June 2006). At this time, multiple different brand and generic statin products were competing, and for some insurance plans, the preferred pricing and rebates for the branded product or competing statins may have influenced how the drug was placed in the formulary (e.g., tier 1 vs tier 2 copayment). 22 A nonpreferential formulary placement of simvastatin was evident in our sample, as illustrated by a slower than expected brand-generic switching rate following generic entry. This could also have influenced switchback rates. Cost-related factors could also be important including how products were placed in formulary tiers and the relative difference in cost sharing across tiers. 23 But we were unable to control for these cost-sharing aspects of individual plan benefit designs, particularly because our retrospective analyses included hundreds of different group plans with annual changes in benefit design. Alternative explanations such as these might explain the differences in switchback rates we observed with simvastatin, as well as with alendronate and amlodipine. Further research is needed to explore these areas.
Our results should be interpreted cautiously. The total number of switchbacks for several drugs was small, especially for gabapentin (no AG and seven generic switchbacks), glimepiride (two AG and six generic switchbacks), and metformin ER (six AG and one generic switchback). Further, we observed high rates of generic-generic switching, and more than 40% of patients initially receiving an AG had switched to a generic by 12 months. Our analysis accounted for this by assigning patients to the last generic product (AG vs generic) prior to switching back to brand, and we censored analyses if either product was no longer on the market. But these market-level nuances still could have influenced our results. For instance, although not statistically significant, our point estimate for generic type trended toward suggesting that switchbacks were less common with the generic than the AG (HR 0.86, 95% CI 0.65-1.15). Indeed, this comparison reached statistical significance for simvastatin (47.5% switched back from an AG, 4.2% switched back from a generic). One factor that may potentially play a role in these results is drug availability and pharmacy stocking. For example, in a national survey of 170 U.S. institutional pharmacies in 2000, most respondents perceived that wholesaler and manufacturer drug back orders were increasing in frequency. 24 Further studies are needed to determine how product availability, internal pharmacy stocking policies, and product cost to the patient may play a role in generic-to-brand switchback patterns.
Of note, our approach might inform future research. Namely, we believe selection and perception biases were reduced through the inclusion of both AG and generic groups, and the combined health plan and clinical data were appropriate for studying patients over a long period of time because this population has been shown to have low patient turnover. 25 Future studies might expand on our work through a focus on narrow therapeutic index drugs because the efficacy and tolerability between generic and brand narrow therapeutic index drugs may be perceived differently. Another future area for study may be to examine switching patterns for authorized versus ANDAapproved generics approved via product-specific testing procedures, using an approach similar to a 2016 study. 26 
Conclusion
To our knowledge, this is the first study to compare generic-to-brand switchback rates between AGs and generics. Our results show a similar likelihood of switchback between AGs and generics, indirectly suggesting equivalent efficacy and tolerability between generic and branded drugs. As suggested by the volatile usage patterns seen in the AG group, future studies assessing product switching may explore the role of product availability on utilization patterns. The effects of individual drugs on switchback likelihood must also be explored further.
